Drugs / LeY CAR T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03851146 | Nov 2016 → Apr 2022 | cancer of unknown primary site | Peter MacCallum Cancer Centre, Australia | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LeY CAR T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03851146 ↗ |
| Known as | LeY-CAR-T | “A Study of Anti-Lewis Y Chimeric Antigen Receptor-T Cells (LeY-CAR-T) in Patients With Solid Tumours” NCT03851146 ↗ |
| Modality | Cell therapy | “Autologous peripheral blood T-lymphocytes transduced with the anti-LeY-scFv-CD28-ζ vector (LeY CAR T cells)” NCT03851146 ↗ |
| Route | Intravenous | “an intravenous infusion of autologous peripheral blood T-lymphocytes transduced with the anti-LeY-scFv-CD28-ζ vector” NCT03851146 ↗ |